Sign In
Buy QGEN
$36.45
+0.760 (+2.13%)
At Close: Jun 03, 2026
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to advance its QuantiFERON latent tuberculosis (TB) test with a new
Qiagen (QGEN) Q1 Earnings and Revenues Lag Estimates
10:51pm, Wednesday, 06'th May 2026
Qiagen (QGEN) came out with quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.58 per share a year ago.
Qiagen (QGEN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:30pm, Wednesday, 06'th May 2026
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to
Levi & Korsinsky Investigates Qiagen N.V. (QGEN) Over Potential Securities Fraud Allegations
07:20pm, Wednesday, 06'th May 2026
New York, New York--(Newsfile Corp. - May 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Qiagen N.V. ("Qiagen N.V.
QGEN Investors Have Opportunity to Join Qiagen N.V. Fraud Investigation with the Schall Law Firm
06:31pm, Wednesday, 06'th May 2026
LOS ANGELES, May 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Qiagen N.V. (“Qi
QIAGEN Reports Full Results for Q1 2026
04:05pm, Wednesday, 06'th May 2026
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today reports full results for the first quarter of 2026 in line with the preliminary ann
Qiagen Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Qiagen N.V. (QGEN)
09:00am, Wednesday, 06'th May 2026
Qiagen projected a low single digit rate first-quarter QuantiFERON growth rate on February 5, 2026. Actual Q1 2026 volumes showed a 5% decline NEW YORK, May 6, 2026 /PRNewswire/ -- Qiagen N.V.
Ongoing Investigation into Qiagen N.V. (QGEN): Contact Levi & Korsinsky About Potential Fraud
08:26pm, Thursday, 30'th Apr 2026
New York, New York--(Newsfile Corp. - April 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Qiagen N.V. ("Qiagen N.V.
SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Qiagen N. V. (NYSE: QGEN). The investigation focuses on Qiagen's executiv
SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Qiagen N.V. (NYSE: QGEN). The investigation focuses on Qiagen's executive
Qiagen N.V. (QGEN) Q1 2026 Earnings Call Transcript
05:41pm, Tuesday, 28'th Apr 2026
Qiagen N.V. (QGEN) Q1 2026 Earnings Call Transcript
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deli
QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026
04:05pm, Thursday, 16'th Apr 2026
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will showcase its oncology workflow applications at the American Assoc
QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel
04:05pm, Tuesday, 14'th Apr 2026
HILDEN, Germany & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for bloodstream in
Qiagen N.V. (NYSE:QGEN) Given Average Rating of “Hold” by Brokerages
04:08am, Saturday, 04'th Apr 2026
Qiagen N.V. (NYSE: QGEN - Get Free Report) has been assigned an average rating of "Hold" from the twelve research firms that are presently covering the company, Marketbeat.com reports. One equities re
